Disulfiram modulated ROS|[ndash]|MAPK and NF|[kappa]|B pathways and targeted breast cancer cells with cancer stem cell-like properties
N C Yip,ivo s fombon,peng liu,S Brown,V Kannappan,angel l armesilla,B Xu,J Cassidy,john l darling,wei wang
DOI: https://doi.org/10.1038/bjc.2011.126
IF: 9.075
2011-01-01
British Journal of Cancer
Abstract:The development of drug resistance remains the major obstacle to the success of breast cancer (BC) chemotherapy. Drug-induced DNA damage triggers the expression of anti-apoptotic proteins, which confer drug resistance upon cancer. The NFκB is one of the major chemoresistance-related anti-apoptotic factors. Many human cancers including BC possess high levels of the constitutive NFκB activity, which can be further induced by some anticancer drugs. High NFκB activity links inflammation and tumourigenesis (Greten et al, 2004). Activated NFκB triggers a series of molecular reactions including up-regulation of anti-apoptotic protein-encoding genes (Dutta et al, 2006) that induce cancer chemoresistance. High NFκB activity has been identified in drug-resistant cancer cells and ectopic over-expression of NFκB can block anticancer drug-induced apoptosis (Wang et al, 1998, 1999, 2004). Previous studies in our laboratory demonstrate that 5-fluorouracil (5-FU)- and gemcitabine (dFdC)-resistant cancer cell lines possess higher NFκB activity (Wang and Cassidy, 2003; Guo et al, 2009). Over-expression of p50 and p65, the two subunits of NFκB, results in increased NFκB activity and induces 5-FU and dFdC resistance (Wang et al, 2004; Guo et al, 2009). Although NFκB is an attractive molecular target for therapeutic intervention, inhibition of NFκB alone can only induce limited cell death. The disappointing clinical trial outcomes from using NFκB inhibitor in treatment of metastatic BC patients (Yang et al, 2006; Cresta et al, 2008) indicate that BC chemotherapy cannot be efficiently improved by only targeting NFκB pathway. Reactive oxygen species (ROS) (Gupte and Mumper, 2009) are a group of oxygen-containing chemical species normally generated from mitochondrial respiratory chain reaction with reactive chemical properties. High ROS activity can damage DNA, protein and lipid membrane leading to apoptosis. In comparison with normal tissues, cancer cells generally possess high ROS activity (Fruehauf and Meyskens, 2007) and can tolerate higher levels of ROS. It has been suggested that further increasing ROS exposure induced by ROS-generating agents will exhaust the cellular antioxidant capacity, pushing cancer cells over the tolerated ROS threshold and leading to apoptosis (Lopez-Lazaro, 2007). Reactive oxygen species-induced apoptosis is highly reliant on persistent activation of pro-apoptotic MAPK pathways (cJun N-terminal kinases (JNKs) and p38) (Nakano et al, 2006) mainly through modulating the activities of mitochondrial pro- and anti-apoptotic proteins by phosphorylation events (Junttila et al, 2008). Many conventional anticancer drugs induce ROS generation and trigger cancer cell apoptosis via ROS–MAPK pathway. However, anticancer drug-induced ROS activation also triggers expression and activation of a number of anti-apoptotic factors including NFκB that dampen the ROS-induced cytotoxic effect (Nakano et al, 2006). Owing to the cross-talk between NFκB and ROS–MAPK pathways, singly targeting either pathway may not be sufficient for inducing cancer cell killing. Therefore, identification of small molecules that simultaneously activate the ROS–MAPK pro-apoptotic pathway and block ROS-induced anti-apoptotic pathways may improve BC chemotherapy. Disulfiram (DS) is a commercially available anti-alcoholism drug (Johansson, 1992). We have previously demonstrated that DS inhibits NFκB activity and enhances 5-FU- and dFdC-induced apoptosis in drug-sensitive and -resistant colon cancer cell lines (Wang et al, 2003; Guo et al, 2009). Disulfiram also potentiates the cytotoxicity of cyclophosphamide, cisplatin and radiation in vitro and protects normal cells in kidney, gut and bone marrow in vivo, while increasing the therapeutic index of a wide range of cytotoxic drugs (Evans et al, 1982; Hacker et al, 1982; Bodenner et al, 1986). The molecular anticancer mechanisms of DS are still largely unknown. The previous publications indicate that the anticancer effect of DS is copper (Cu) dependent (Nobel et al, 1995; Cen et al, 2002, 2004; Chen et al, 2006). Copper has a crucial role in redox reactions and triggers generation of ROS in human cells. Disulfiram/copper is a strong ROS inducer (Nobel et al, 1995) and proteasome-NFκB pathway inhibitor (Chen et al, 2006). Combination of DS with Cu may target cancer cells by simultaneously tackling both ROS and NFκB. Cancer derives from a very small fraction (1%) of cancer stem cells (CSCs) (Dalerba et al, 2007), which are relatively quiescent and express multidrug resistant and anti-apoptotic proteins (Marques et al, 2010; Storci et al, 2010). Conventional anticancer drugs target the proliferating and differentiated tumour bulk, but fail to eradicate the CSCs, which become the source of tumour recurrence. Aldehyde dehydrogenases (ALDHs) are functional markers of normal and breast cancer stem cells (BCSCs) (Ginestier et al, 2007; Marcato et al, 2011). It recently reported that targeting ALDH1A1 gene can target ovarian CSCs (Landen et al, 2009). Disulfiram is a specific inhibitor of ALDHs (Johansson, 1992; Lam et al, 1997). Therefore, it may also be an inhibitor of BCSCs. This study demonstrated that in combination with physiological concentration of Cu, DS was highly cytotoxic to BCSCs and synergistically enhanced the cytotoxicity of paclitaxel (PAC) in BC cell lines. Disulfiram is a Food and Drug Administration-approved anti-alcoholism drug used in clinic with extensive available pre-clinical and clinical data (Eneanya et al, 1981). Our study demonstrated high cytotoxicity of DS to BC cell lines in a Cu-dependent manner. Using Cu to treat cancer has a long history (Hieger, 1926; Gupte and Mumper, 2009), but the intracellular transport of Cu is still one of the major hurdles for its clinical efficacy. The transport of Cu into cell is mediated and tightly controlled by the copper transporter, Ctr1. A derivative of DS, N,N-diethyldithiocarbamate (deDTC), binds to Cu forming a Cu(deDTC)2 complex, which improves the intracellular trafficking of Cu and this is probably responsible for DS-induced apoptosis (Cen et al, 2004). Disulfiram can also penetrate into cancer cells to form Cu(deDTC)2 with intracellular Cu. In comparison with normal tissues, many cancers including BC possess higher levels of Cu (two- to three-fold) (Mulay et al, 1971; Margalioth et al, 1983; Rizk and Sky-Peck, 1984), which may enable DS to target cancer cells selectively (Evans et al, 1982; Hacker et al, 1982; Bodenner et al, 1986; Chen et al, 2006; Iljin et al, 2009). In line with a previous report (Wickstrom et al, 2007), a biphasic cytotoxic effect of DS was observed in BC cell lines tested in complete medium without Cu supplement (Figure 1A). Breast cancer cells were killed at low concentration, but revived at higher DS concentrations (~10 μM). The mechanism of the biphasic effect remains unclear. A degradation product of DS may compete trace amounts of Cu, block formation of Cu(deDTC)2 and inhibit transport of Cu into cells (Cen et al, 2004). We have previously reported that DS enhances the cytotoxicity of 5-FU and gemcitabine in colon and BC cell lines (Wang et al, 2003; Guo et al, 2009). Here, we demonstrated synergistic cytotoxic effect of DS/Cu and PAC on BC cell lines. Previous studies demonstrate that in combination with Cu, DS induces ROS activity in melanoma cell lines (Cen et al, 2002; Morrison et al, 2010). The recent study from Dou's group demonstrates that gold–dithiocarbamato complexes strongly induce ROS and inhibit proteasome activity in BC cells (Zhang et al, 2010). In consistence with these results, our study showed that DS/Cu induced ROS activity, which was responsible for DS/Cu-induced cytotoxicity in BC cell lines. The ROS-induced apoptosis is commonly mediated by the persistent activation of JNK and p38 MAPK pathways (Junttila et al, 2008). In our study, both JNK and p38 pathways were persistently (over 24 h) activated (phosphorylation of cJun and p38) by DS/Cu and blocked by NAC. cJun N-terminal kinase and p38 inhibitors reduced cytotoxicity of DS/Cu, although to a lesser degree than ROS inhibition. Therefore, ROS-activated JNK and p38 pathways were, at least partially, responsible for ROS-induced apoptosis. The persistent activation of JNK and p38 induces apoptosis via mitochondrial apoptotic pathways (Junttila et al, 2008). The DS/Cu-induced apoptosis was confirmed by DNA content and PARP protein cleavage. The expression of Bax and Bcl2 proteins was induced and suppressed by DS/Cu, respectively, leading to increased Bax/Bcl2 ratio. The elevated Bax/Bcl2 ratio indicated that the intrinsic apoptotic pathway may be involved in DS/Cu-induced apoptosis. Owing to the high proliferative rate and energy requirement, cancer cells are under higher ROS stress than their normal counterparts. High levels of ROS can damage DNA, mitochondrial inner membrane and membrane phospholipids leading to apoptosis (Gupte and Mumper, 2009). However, ROS also activate a wide range of anti-apoptotic factors. The effect of ROS on cancer cells depends on the balance between ROS-induced pro- and anti-apoptotic factors. The NFκB is one of the most important ROS-induced anti-apoptotic factors (Gloire et al, 2006). The NFκB activation in turn inhibits ROS and JNK, p38 activation and ultimately inhibits ROS-induced apoptosis. Breast cancer cell lines commonly possess high levels of constitutive NFκB activity (Wang et al, 2004; Guo et al, 2009; Xu et al, 2009). Consistent with previous publications (Wang et al, 2003; Guo et al, 2009), DS/Cu inhibited NFκB activity in BC cell lines. This indicates that DS/Cu may induce apoptosis of BC cells by simultaneously inducing ROS generation and inhibiting ROS-NFκB pathway. The effect of DS/Cu on the regeneration of minimal-residual cancer cells, the main source of cancer relapse after chemotherapy, was examined using a clonogenic assay, a gold measure to detect the cell ‘reproductive death’ after cytotoxic agent treatments (Franken et al, 2006). In contrast to the moderate inhibiting effect of PAC, DS and Cu on clonogenicity of BC cells, the colony formation was significantly reduced or completely eradicated by DS/Cu and PAC/DS/Cu, respectively (Figure 4A). Disulfiram/copper reverses cancer cell chemoresistance induced by a wide range of different mechanisms (Wang et al, 2001, 2003, 2004; Guo et al, 2009). It has been widely accepted that CSCs are responsible for tumour recurrence and may display significant resistance to different cytotoxic drugs (Liu and Wicha, 2010). The effect of DS/Cu on clonogenicity of BC cell lines prompted us to examine the effect of DS/Cu on BCSCs. Disulfiram is an inhibitor of ALDHs. Human ALDHs are a superfamily with 19 members involved in detoxifying a wide range of aldehydes to their corresponding weak carboxylic acids (Sladek, 2003); ALDH1A1 has been identified as a functional marker of several different types of CSCs including BCSCs (Ginestier et al, 2007; Alison et al, 2011). It recently reported that knockdown of ALDH1A1 expression using siRNA can target ovarian CSCs and potentiate cytotoxicity of taxane and platinum in vitro and in vivo (Landen et al, 2009). Recently, Marcato et al (2011) identify ALDH1A3 as another major marker of BCSCs. Therefore, ALDHs may be redundantly expressed in different cancer types and targeting one isoform may not be sufficient for CSCs targeting. Disulfiram is a strong inhibitor for both cytosol and mitochondrial ALDHs (Eneanya et al, 1981; Lam et al, 1997). Kast and Belda-Iniesta (2009) hypothesised that targeting ALDHs by DS may reverse chemoresistance in glioblastoma. Our study is the first report of using DS to target BCSCs. The ALDH+VE population in BCSCs was significantly inhibited by DS/Cu. The ability of BC cell lines to form mammospheres was completely inhibited by 24 h exposure to DS/Cu or PAC/DS/Cu (Figure 4B). The effect of DS/Cu on CSCs was also confirmed by the reduction of the CD24Low/CD44High population (Figures 4C and D). The detailed molecular mechanisms underlying the effect of DS/Cu on BCSCs are unclear. Aldehyde dehydrogenases detoxify intracellular aldehydes, which can form adducts with glutathione, nucleic acids and amino acids leading to cell death (Marchitti et al, 2008). The high expression of ALDHs in CSCs may be protective. Mammalian cornea cells contain abundant ALDH, which has critical role in scavenging ROS and reduce UV-induced oxidative stress (Estey et al, 2007). Aldehyde dehydrogenase deficiency in central nervous system is associated with progressive neurodegeneration (Marchitti et al, 2007). Inhibition of NFκB pathway and induction of ROS result in reduction of stem-like properties in CSCs derived from pancreatic cancer and leukaemia (Greten et al, 2004; Jin et al, 2010; Rausch et al, 2010). Disulfiram/copper may target BCSCs by simultaneously inhibiting NFκB and activating ROS activity. This work is supported by Breast Cancer Campaign, UK. P Liu is a PhD student supported by RIHS and Deten Pharmaceutical Ltd, Xi'an, China.